MDxHealth (NASDAQ:MDXH) Stock Rating Lowered by Zacks Investment Research

MDxHealth (NASDAQ:MDXHGet Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Thursday, Zacks.com reports.

According to Zacks, “MDxHealth SA is a healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. MDxHealth SA is based in Belgium. “

NASDAQ:MDXH opened at $7.88 on Thursday. The company’s 50 day moving average is $8.11. MDxHealth has a 52 week low of $7.01 and a 52 week high of $13.17.

Large investors have recently bought and sold shares of the company. Altium Capital Management LP bought a new position in shares of MDxHealth during the fourth quarter valued at approximately $344,000. Ghisallo Capital Management LLC bought a new position in MDxHealth in the 4th quarter worth approximately $190,000. Bleichroeder LP bought a new position in MDxHealth in the 4th quarter worth approximately $18,643,000. Finally, Perkins Capital Management Inc. bought a new position in MDxHealth in the 4th quarter worth approximately $857,000.

MDxHealth Company Profile (Get Rating)

MDxHealth SA operates as a molecular diagnostics company in Belgium, the Netherlands, Spain, Poland, Italy, the United States, rest of European Union, and internationally. The company develops and commercializes epigenetic and other molecular tests for cancer assessment and the personalized treatment of patients.

Read More

Get a free copy of the Zacks research report on MDxHealth (MDXH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MDxHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDxHealth and related companies with MarketBeat.com's FREE daily email newsletter.